

**"PUBLIC DISPLAY COPY" 8EHQ-1297-14087**

## TSCA CBI STATUS:

**CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)**Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ Contains CBI).

Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

<b>1.0 SUBMISSION TYPE</b> <input type="checkbox"/> Contains CBI <input type="checkbox"/> 8(d) <input checked="" type="checkbox"/> 8(e) <input type="checkbox"/> FYI <input type="checkbox"/> 4 <input type="checkbox"/> OTHER: Specify _____ <input type="checkbox"/> Initial Submission <input type="checkbox"/> Follow-up Submission <input type="checkbox"/> Final Report Submission Previous EPA Submission Number or Title if update or follow-up: _____ Docket Number, if any: # _____ <input type="checkbox"/> continuation sheet attached		
<b>2.1 SUMMARY/ABSTRACT ATTACHED</b> (may be required for 8(e): optional for §4, 8(d) & FYI)  <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	<b>2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID</b>  <p style="text-align: center; font-weight: bold;">97-112</p>	<b>2.3 FOR EPA USE ONLY</b>
<b>3.0 CHEMICAL/TEST SUBSTANCE IDENTITY</b> <input type="checkbox"/> Contains CBI <i>Reported Chemical Name (specify nomenclature if other than CAS name):</i> CAS# _____ Purity _____ % <input type="checkbox"/> Single Ingredient <input type="checkbox"/> Commercial/Tech Grade <input type="checkbox"/> Mixture <div style="text-align: center; font-size: 1.5em; font-weight: bold; margin: 10px 0;">COMPANY SANITIZED</div> <div style="display: flex; justify-content: space-between;"> <span>Trade Name: _____</span> <span>Common Name: <u>benzyl heterocycle</u></span> </div> <div style="display: flex; justify-content: space-between;"> <span>CAS Number _____</span> <span>NAME _____</span> <span>% WEIGHT _____</span> </div> Other chemical(s) present in tested mixture <input type="checkbox"/> continuation sheet attached		
<b>4.0 REPORT/STUDY TITLE</b> <input type="checkbox"/> Contains CBI <p style="text-align: center; font-weight: bold;">Pilot Oral Teratology Study in Rats</p> <div style="text-align: right; font-size: 1.2em; margin-top: 10px;">8EHQ-97-14087 8498000056</div> <input type="checkbox"/> continuation sheet attached		
<b>5.1 STUDY/TSCATS INDEXING TERMS</b> [CHECK ONE] HEALTH EFFECTS (HE): <input checked="" type="checkbox"/> ENVIRONMENTAL EFFECTS (EE): _____ ENVIRONMENTAL FATE (EF): _____		
<b>5.2 STUDY/TSCATS INDEXING TERMS</b> (see instructions for 4 digit codes) STUDY _____ SUBJECT _____ ROUTE OF _____ VEHICLE OF <b>CORN</b> TYPE: <u>TERA</u> ORGANISM (HE, EE only): <u>RATS</u> EXPOSURE (HE only): <u>GAVG</u> EXPOSURE (HE only): <u>OIL</u> Other: _____ Other: _____ Other: _____ Other: _____		
<b>6.0 REPORT/STUDY INFORMATION</b> <input type="checkbox"/> Contains CBI <input type="checkbox"/> Study is GLP Laboratory <u>FMC Toxicology Laboratory</u> Report/Study Date <u>on-going</u> Source of Data/Study Sponsor (if different than submitter) _____ Number of pages _____ <input type="checkbox"/> continuation sheet attached		
<b>7.0 SUBMITTER INFORMATION</b> <input type="checkbox"/> Contains CBI <div style="display: flex; justify-content: space-between;"> <div>           Submitter: <u>Linda M. Clark</u>            Company Name: <u>FMC Corporation</u>  <u>Philadelphia, PA 19103</u> </div> <div>           Title: <u>Product Reg. Affairs</u> Phone: <u>(215) 299-6133</u>            Company Address: <u>1735 Market Street</u>            Submitter Address (if different): _____         </div> </div> Technical Contact: <u>Christine Freeman</u> Phone: <u>(609) 951-3731</u> <input type="checkbox"/> continuation sheet attached		
<b>8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS</b> <input type="checkbox"/> Contains CBI <input type="checkbox"/> continuation sheet attached		

 Submitter Signature: Linda M Clark Date: 12/9/97

**TSCA HEALTH & SAFETY STUDY COVER SHEET - revised 6/25/96**  
**9.0 CONTINUATION SHEET**

***"PUBLIC DISPLAY COPY"***

**TSCA CBI STATUS:**

**CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)**

Clearly mark the confidential information with bracketing and check the box in the appropriate section (*Contains CBI*).  
Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

Submitter Tracking Number/Internal ID

**97-112**

CONTINUED FROM COVER SHEET SECTION # 2.1

☐ *Contains CBI*

**Based on reduced fetal body weights, increases in early and late resorptions and fetal death, and malformations and variations noted among 10/mg/kg/day fetuses, FMC Corporation is herewith submitting the following information to EPA pursuant to TSCA 8(e).**

**Ten pregnant rats/group were administered dosages of 0, 10, 50, 1200, 250, 500, or 1000 mg/kg/day of a *benzyl heterocycle* on days 6-19 of gestation.**

**100% resorptions were noted among all dams receiving 50 kg/kg/day and greater. A biologically significant increase in the number of early resorptions, late resorptions, and dead fetuses were noted among 10/mg/kg/day dams. Surviving fetuses from dams receiving 10 mg/kg/day had reduced body weights and a biologically significant increase in the incidence of cleft palate (a malformation) and pallor (a variation).**